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Abstract
Objectives—Secondary analysis of clinical trial data suggests visit-to-visit variability (VVV) of 
blood pressure is strongly associated with the incidence of cardiovascular disease. Measurement of 
blood pressure in usual practice settings may be subject to substantial error, calling into question 
the value of VVV in real-world settings.
Methods—We analyzed data on adults ≥ 65 years of age with diagnosed hypertension who were 
taking antihypertensive medication from the Cohort Study of Medication Adherence among Older 
Adults (n=772 with 14 or more blood pressure measurements). All blood pressure measurements, 
taken as part of routine out-patient care over a median of 2.8 years, were abstracted from patients’ 
medical charts.
Results—Using each participant’s first 7 systolic blood pressure (SBP) measurements, the mean 
intra-individual standard deviation was 13.5 mmHg. The intra-class correlation coefficient for the 
standard deviation based on the first 7 and second 7 SBP measurements was 0.28 (95% CI: 0.20 – 
0.34). Individuals in the highest quintile of standard deviation of SBP based on their first 7 
measurements were more likely to be in the highest quintile of VVV using their second 7 
measurements (observed/expected ratio = 1.71, 95% CI: 1.29 – 2.22). Results were similar for 
other metrics of VVV. The intra-class correlation coefficient was lower for diastolic blood pressure 
(DBP) than SBP.
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Conclusions—These data suggest VVV of SBP measured in a real-world setting is not random. 
Future studies are needed to assess the prognostic value of VVV of SBP assessed in routine 
clinical practice.
Keywords
Blood pressure; variability; reproducibility; health services research
Several recent studies have reported a strong and graded association between visit to visit 
variability (VVV) of blood pressure and the incidence of coronary heart disease, stroke, and 
all-cause mortality[1, 2]. These associations were present after adjustment for several 
potential confounders, including mean blood pressure level. Furthermore, VVV has been 
demonstrated to be reproducible, suggesting it may have value as a predictor of 
cardiovascular disease risk[3]. While these data may have profound implications for the 
treatment of hypertension, they were derived from large randomized controlled trials and 
observational cohort studies wherein blood pressure measurements were performed as part 
of a research protocol at set time periods following standardized procedures.
The use of electronic medical records provides an opportunity to make VVV of blood 
pressure available for use in routine clinical practice. However, blood pressure measurement 
in the office setting is often criticized for having systematic and random error[4, 5]. The 
degree to which VVV of blood pressure, calculated using clinic measurements, reflects real 
variability versus measurement error is uncertain. If VVV using clinic measurements is 
reproducible, it may provide an important tool for assessing a patient’s future cardiovascular 
disease risk and guiding treatment decisions.
The goal of this analysis was to determine the degree to which VVV is reproducible when 
using blood pressure measured as part of routine care in the out-patient setting. Additionally, 
we sought to identify patient factors associated with a lack of reproducibility. We analyzed 
blood pressure data, obtained through the abstraction of electronic medical records from a 
large managed care organization for participants in the Cohort Study of Medication 
Adherence among Older Adults (CoSMO). A priori, we chose to determine the 
reproducibility of VVV based on the first 4 versus second 4 and first 7 versus second 7 
blood pressure measurements to match a study which calculated reproducibility of VVV in 
the setting of two clinical trials[3].
METHODS
Study Population and Timeline
The CoSMO study design, recruitment flowchart, and baseline characteristics of participants 
have been previously described[6]. In brief, adults, 65 years and older who were receiving 
treatment for essential hypertension were randomly selected from the roster of a large 
managed care organization in southeastern Louisiana. Recruitment was conducted from 
August 21, 2006 to September 30, 2007, and 2,194 participants were enrolled. Participants 
were actively followed through February 2010. All participants provided verbal informed 
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consent, and CoSMO was approved by the Ochsner Clinic Foundation’s Institutional Review 
Board and the Privacy Board of the managed care organization.
Study Measures
Recruitment and survey data were collected via telephone by trained interviewers. 
Participant characteristics, including demographics, cigarette smoking and duration of 
hypertension were assessed through self-report. Based on ICD-9 codes recorded in the 
managed care organization’s administrative database, a weighted comorbidity score was 
generated using the Charlson comorbidity index[7]. The number and classes of 
antihypertensive medications being taken by each participant were downloaded from the 
managed care organization’s pharmacy database.
Blood pressure data
Trained research staff abstracted blood pressure data from electronic medical records for 
outpatient clinic visits occurring the year prior to the baseline interview through the 
completion of the second CoSMO follow-up interview (median time = 2.8 years; maximum 
= 4 years). All blood pressure measurements included in this study were obtained as part of 
clinical care and no structured measurement approaches were prescribed. Data abstraction 
included systolic blood pressure (SBP) and diastolic blood pressure (DBP) levels, patient 
position, and date of blood pressure measurement. For the current analysis, only seated 
blood pressure measurements were used. In our sample, 79% of visits had only 1 recorded 
blood pressure measurement while 19% of visits had 2 recordings, and < 3% of visits had 3 
or more recordings. Blood pressure levels were averaged for visits with more than one 
measurement taken. Blood pressure data were available for 2,130 CoSMO participants.
VVV of blood pressure
VVV metrics were calculated for the first 4 and second 4 blood pressure measurements and 
again for the first 7 and second 7 blood pressure measurements. The first 4 blood pressure 
measurements occurred over a median period of 7.2 months (range: 2 weeks to 34 months), 
while the second 4 blood pressure measurements occurred over a median period of 7.4 
months (range: 1 week to 30 months). The first 7 and second 7 blood pressure measurements 
occurred over a median period of 11.5 months (range: 2 months to 28 months) and 11.0 
months (range: 2 months to 29 months), respectively. For the current analyses, we evaluated 
seven VVV metrics: standard deviation, standard deviation independent of the mean 
(SDIM), coefficient of variation, peak size, trough size, successive variation (SV), and 
average real variability (ARV) (see Appendix for formulas)[3]. Standard deviation has been 
used in prior studies as the primary measure of VVV. Because standard deviation is 
correlated with mean SBP, we also evaluated SDIM. Coefficient of variation provides a 
normalized measure of variability. Peaks and troughs in blood pressure were defined as the 
difference between the mean and the maximum blood pressure (for peak) and mean and the 
minimum blood pressure (for trough). The SV and ARV take the order of the blood pressure 
measurements into account and quantify variability between adjacent readings.
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Participant characteristics were calculated for the overall CoSMO study population and for 
individuals with at least 8 and at least 14 blood pressure measurements. Herein, we describe 
the analysis for individuals with 8 or more blood pressure measurements (n=1,580) 
comparing the first 4 and second 4 blood pressure measurements. Analogous analyses were 
conducted for individuals with 14 or more blood pressure measurements (n=772) and 
comparing the first 7 and second 7 blood pressure measurements. Using the first 4 and 
second 4 abstracted measurements separately, the mean blood pressure level and each of the 
seven VVV metrics were calculated. Additionally, the Spearman correlation coefficient 
between the seven VVV metrics and the mean blood pressure level was calculated. Next, the 
intra-class correlation coefficients (ICC) for the mean blood pressure level and each of the 
seven VVV metrics between the first 4 and second 4 measurements were calculated. The 
95% confidence interval for each ICC was calculated using a 10,000 iteration bootstrap. Two 
sensitivity analyses were conducted to determine the reproducibility of VVV using alternate 
time periods. First, we calculated the ICC limited to blood pressure measurements that 
occurred at least one week apart (n=1,547 participants with 8 or more measurements and 
n=677 with 14 or more measurements separated by one or more week). Second, we 
calculated the ICC comparing VVV of blood pressure during the first 18 months of follow-
up with the second 18 months of follow-up (n=1,180 participants with 4 or more 
measurements and n=453 with 7 or more measurements in each 18 month time period). The 
above analyses for reproducibility of VVV were performed for SBP and DBP, separately.
Next, the population was divided into quintiles based on the distribution of standard 
deviation using the first 7 SBP values and, separately, using the second 7 SBP values. 
Weighted Kappa statistics were used to calculate the agreement between these categories[8]. 
Amongst individuals in the highest quintile of standard deviation of SBP based on their first 
7 SBP measurements, we calculated the observed and expected number of participants in the 
highest quintile of standard deviation based on their second 7 SBP measurements. 
Additionally, the observed and expected number of participants in the lowest quintile of 
standard deviation of SBP was calculated. The categorical analyses of reproducibility (i.e., 
weighted Kappa and observed-to-expected ratios) were also performed using SDIM as the 
VVV metric.
Finally, we determined patient characteristics associated with low levels of VVV 
reproducibility. For this analysis, individuals whose standard deviation of SBP based on 
their second 7 measurements was 8 or more mmHg higher or −8 or more lower than the 
standard deviation of SBP for their first 7 measurements were defined as having a low level 
of reproducibility. The cut-point of 8 mmHg was chosen to represent the highest quintile of 
change in standard deviation of SBP over the two time periods. Using logistic regression, the 
odds ratio for low reproducibility was calculated in unadjusted and age, race, gender, and 
mean SBP adjusted models. All analyses were conducted in SAS version 9.2 (SAS Institute, 
Cary NC).
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The mean age of CoSMO study participants was 75.0 (standard deviation = 5.6) years, 59% 
were women and 31% were African-American (Table 1). The majority of participants had 
hypertension for ≥ 10 years and was taking 3 or more classes of antihypertensive 
medications. Compared to the overall CoSMO population, participants with ≥ 8 and ≥ 14 
blood pressure measurements were more likely to have diabetes mellitus, a history of 
myocardial infarction or stroke, a Charlson comorbidity score ≥ 2, and to be taking more 
antihypertensive medication classes. Digit preference was present in these data. For those 
with at least 8 blood pressure measurements, 47% of all SBP readings end in zero and 49% 
of all DBP readings end in zero. Additionally, for those with at least 14 blood pressure 
measurements, 48% of all SBP readings end in zero and 49% of all DBP readings end in 
zero Of all SBP recordings, 9% were exactly 140 mmHg, and 5% of all DBP readings were 
exactly 90 mmHg.
Based on the first 4 measurements, the mean SBP was 135.4 mmHg, the intra-individual 
standard deviation was 12.2 mmHg and the SDIM was 12.1 mmHg (Table 2). Each VVV 
metric except SDIM was correlated with mean SBP. Results were similar using the first 7 
SBP measurements. The mean DBP, based on the first 4 measurements, was 75.6 mmHg and 
the intra-individual standard deviation and SDIM were 7.0 mmHg and 7.1 mmHg, 
respectively. For DBP, only the coefficient of variation was correlated with mean DBP (ρ = 
−0.18). Similar patterns were present when considering the first 7 DBP measurements.
The top panel of Table 3 shows the ICC for the first 4 versus second 4 measurements and 
first 7 versus second 7 measurements of mean SBP and each VVV metric for SBP. The ICC 
was highest for comparing the first 4 and second 4 and first 7 and second 7 intra-individual 
mean SBP levels. For the VVV measures, the ICC was highest for standard deviation of SBP 
(0.19, 95% CI: 0.13 – 0.25 comparing the first versus second 4 measurements and 0.28, 95% 
CI: 0.20 – 0.34 for the first versus second 7 measurements). The ICCs for DBP are shown in 
the bottom panel of Table 3. For DBP, the highest ICC for the VVV measures was for 
coefficient of variation (0.15, 95% CI: 0.10 – 0.20 comparing the first versus second 4 
measurements and 0.21, 95% CI: 0.14 – 0.27 for the first versus second 7 measurements). 
The ICCs were similar in sensitivity analyses limited to blood pressure measurements taken 
one or more week apart (Supplemental Table 1). The ICC was higher for VVV metrics 
calculated using all blood pressure measurements available from two consecutive 18 month 
time periods (Supplemental Table 2). For example, amongst individuals with 7 or more 
blood pressure measurements in each time period, the ICC comparing the standard deviation 
of blood pressure based on all measurements from months 0 to 18 with months 19 through 
36 was 0.36 (95% CI: 0.26 – 0.45).
The weighted kappa assessing the concordance of quintile of standard deviation based on the 
first 7 and second 7 SBP measurements was 0.14 (95% CI: 0.09 – 0.19; Table 4 top panel). 
The analogous weighted kappa statistic for SDIM was 0.10 (95% CI: 0.05 – 0.15; Table 4 
bottom panel). Participants in the highest quintile of standard deviation of SBP based on 
their first 7 measurements were more likely to be in the highest quintile based on their 
second 7 measurements (observed-to-expected ratio =1.71, 95% CI: 1.29 – 2.22). The 
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observed-to-expected ratio for being in the lowest quintile of standard deviation of SBP was 
1.40 (95% CI: 1.02 – 1.86). For SDIM, the observed-to-expected ratio for being in the 
highest quintile was 1.53 (95% CI: 1.14 – 2.03) and for the lowest quintile was 1.24 (95% 
CI: 0.89 – 1.69).
In unadjusted models, female gender, higher mean SBP and pulse pressure, and the use of 
angiotensin receptor blockers were associated with lower reproducibility of VVV of blood 
pressure (Table 5). After adjustment for age, race, and gender, higher mean SBP remained 
associated with a higher odds ratio for low reproducibility of VVV of blood pressure. 
Additionally, after adjustment for age, race, gender, and mean SBP, use of angiotensin 
receptor blockers was associated with an increased odds ratio for low reproducibility.
DISCUSSION
Data from the current study provide insight into the reliability of VVV calculated based on 
blood pressure measurements taken for the purpose of providing clinical care. Using blood 
pressure measurements taken for routine care and not research purposes, intra-individual 
VVV was not random. Comparing the first and second 7 SBP measurements, the ICC was 
0.28 for standard deviation and 0.22 for SDIM. Furthermore, individuals in the highest 
quintile of VVV based on their initial 7 measurements were significantly more likely to be 
in the highest VVV quintile based on their second 7 measurements.
The reproducibility of VVV of blood pressure in the current study using non-standardized 
clinic-based measurements is consistent with results generated from two prior research 
studies, the UK-TIA and the European Carotid Surgery Trial (ECST)[3]. Participants in UK-
TIA and ECST, all of whom had a transient ischemic attack (TIA) or minor ischemic stroke, 
were followed a mean of 4 and 6.1 years, respectively, with blood pressure measured at 
regular intervals: every four months in the UK-TIA and at a four month follow-up visit and 
annually thereafter in ECST. The ICC for standard deviation of SBP based on four 
measurements was 0.25 and 0.16 in the UK-TIA and ECST, respectively (compared to 0.19 
in the current study) and 0.32 and 0.18, respectively, based on 7 measurements (compared to 
0.28 in the current study). The current study extends these data from patients with TIA to a 
population with hypertension and from blood pressure measured as part of a study protocol 
to measurements taken as part of clinical care. While future studies on the prognostic 
importance of VVV in outpatient settings on outcomes are needed, the current study 
provides important new data highlighting the reproducibility of VVV using routine 
outpatient visit data.
The lower degree of reproducibility for VVV compared to mean SBP identified in the 
current study has important implications for both future research and, possibly, for patient 
care. First, studies estimating the risk for outcomes (e.g., stroke) associated with VVV may 
provide biased estimates[9]. The error involved in estimating mean blood pressure levels 
based on a single measurement is well established and substantial research has documented 
the importance of correction for regression dilution[10, 11]. The lower ICC for VVV 
metrics, compared to mean blood pressure levels, in the current study suggests correction for 
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regression dilution bias may be important for studies evaluating the relation of VVV with 
subsequent outcomes.
Second, in the current study, reproducibility of VVV was higher when based on a larger 
number of measurements. For example, the ICC for standard deviation was 1.19 when based 
on 4 measurements and 0.28 based on 7 measurements. Therefore, investigators should be 
cautious in undertaking and interpreting data from studies based on only a few blood 
pressure measurements per person. In such situations, the lack of an association between 
VVV and outcomes (e.g., stroke) may be due to an unreliable estimate of VVV. However, as 
an association between VVV and all-cause mortality has been detected with as few as three 
blood pressure measurements, understanding the limitations of using few data points 
requires more study[2].
Third, future studies are needed to determine the optimal number of blood pressure 
measurements needed to obtain reliable and valid estimates of VVV. In a simulation, 
Rothwell showed the difference between an individual’s observed and true blood pressure 
differed by level of intra-individual VVV. Also, the absolute difference between observed 
and true mean blood pressure level was less than 5 mmHg using 5 or more blood pressure 
measurements[1]. However, the Rothwell study did not address reproducibility of VVV 
metrics. Using more blood pressure measurements provides a greater degree of 
reliability[12]. There are limitations to using a greater number of blood pressure 
measurements to estimate VVV. In the clinical setting, many individuals may have a limited 
number of blood pressure measurements and, thus, may be excluded from the calculation of 
VVV. In the current study of hypertensive older adults, those with 14 or more blood pressure 
measurements had more comorbidities than the population as a whole. Excluding individuals 
with only a few blood pressure measurements may lead to a smaller study sample which is 
systematically different from the source population. It would beneficial for future studies to 
evaluate the optimal number of blood pressure measurements needed to reliably estimate 
VVV.
With the advent and wider use of electronic medical records and computer applications, the 
reporting of VVV in routine outpatient settings may be feasible. Calculating VVV in the 
setting of outpatient care may have important implications. A recent meta-analysis of data 
from randomized trials comparing antihypertensive regimens (with each other and with 
placebo) suggested that use of calcium channel blockers and thiazide-type diuretics lead to 
lower VVV of blood pressure, whereas use of ACE-inhibitors and beta blockers lead to 
greater variability[13]. If VVV measured in the clinical setting is determined to be related to 
adverse outcomes and specific antihypertensive medications differentially affect VVV of 
blood pressure, these findings may impact the approach used for blood pressure 
measurement and patient monitoring. In those patients with both high average blood 
pressure levels (i.e. SBP/DBP ≥ 140/90 mmHg) and high VVV of blood pressure, an 
additional treatment target (i.e., lower VVV of blood pressure) beyond a reduction in 
average blood pressure may be recommended to reduce their risk for cardiovascular events. 
Additionally, low medication adherence has been suggested as a possible factor explaining 
the link between antihypertensive medication use and higher VVV of blood pressure[2]. 
While there are other biological reasons for high VVV of blood pressure (e.g., arterial 
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stiffness, inflammation, sympathetic nervous system overactivity), capturing VVV in the 
outpatient clinical setting may be useful for identifying low antihypertensive medication 
adherence for some patients[12, 14, 15]. Future research is needed on the relation between 
VVV and outcomes in the clinic setting.
The goal of the current analysis was to assess the reproducibility of VVV of blood pressure 
based on measurements taken for patient care. However, there are several important aspects 
of VVV of blood pressure assessed in clinical practice that were beyond the scope of this 
analysis. These include assessing the impact of antihypertensive medication adherence, drug 
classes, and changes in prescription regimen on VVV of blood pressure. Additionally, the 
association of VVV of blood pressure on outcomes including cardiovascular and renal 
disease warrants investigation.
The current results should be interpreted in the context of certain limitations. First, while 
almost all CoSMO participants had blood pressure measurements available, only 772 of the 
2,194 CoSMO study participants had 14 or more blood pressure measurements taken during 
the study period. Second, the CoSMO study was restricted to participants ≥ 65 years of age 
with hypertension and taking antihypertensive medications. Evaluation of the reproducibility 
of VVV in younger adults and those without hypertension, especially those not taking 
antihypertensive medications, is needed. However, studying the reproducibility of VVV in 
these adults was beyond the scope of the current study. Third, blood pressure measurements 
were not taken at set time periods and only a median of 2.8 years of blood pressure data 
(maximum of 4 years) were available. Fourth, only a single blood pressure measurement was 
recorded in patients’ charts for 79% of visits. Having multiple blood pressure measurements 
at each visit may increase the reproducibility of VVV of blood pressure. Data were not 
available on whether blood pressure was taken manually or with automated devices. 
However, at the time of the study, manual blood pressure was the primary mode of 
measurement in the outpatient clinics. Additionally, the high degree of digit preference also 
is indicative of manual blood pressure measurement. Prior studies have suggested there is 
higher reliability in blood pressure measurements, especially among patients with 
hypertension, when taken by automated measurement devices[16]. Therefore, it can be 
posited that higher reproducibility will be present when automated devices are used. Future 
studies of blood pressure measurement technique (manual or automatic) on reproducibility 
of VVV are needed. Despite these limitations, the current study has several notable 
strengths. These include a well characterized study population with a substantial number of 
African-Americans and whites and men and women. Additionally, the results were markedly 
consistent, regardless of VVV metric analyzed.
Intra-individual VVV derived using outpatient blood pressure measurements taken as part of 
routine patient care is not a random phenomenon. The level of reproducibility observed in 
the current study is consistent with data obtained from randomized controlled trials of 
individuals with cerebrovascular disease wherein blood pressure was measured following 
protocols at set time intervals. Future studies on the prognostic value of VVV of blood 
pressure measured for routine outpatient care on cardiovascular and renal disease outcomes 
are warranted.
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Appendix. Formulas used to calculate VVV metrics
Formula 1
Standard deviation (SD) SD =










 is derived by fitting a curve to
SD = k × x̄a, where k is a constant
Formula 3




Peak size = max xi − x
Formula 5
Trough size
Trough size = x − min xi
Formula 6
Successive variation (SV) SV =
1
n − 1 ∑i = 1
n − 1





for i = 1, 2, …, n.
Formula 7
Average real variability (ARV) ARV =
1
n − 1 ∑i = 1
n − 1
∣ BPi + 1 − BPi ∣
An explanation of these metrics is provided in Reference 3 (Howard SC, 2009)
Abbreviation definition list
VVV visit-to-visit variability
SBP systolic blood pressure
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CoSMO Cohort Study of Medication Adherence among Older Adults
SDIM standard deviation independent of the mean
CV coefficient of variation
SV successive variation
ARV average real variability
ICC Intraclass correlation coefficient
ECST European Carotid Surgery Trial
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Table 1
Characteristics of the overall CoSMO study population and those with 8 or more and 14 or more blood 
pressure measurements available for analysis.
Overall
(n=2,194)
At least 8 BP
measurements
(n=1,580)
At least 14 BP
measurements
(n=772)
Age, years, mean (SD) 75.0 (5.6) 75.2 (5.5) 75.4 (5.4)
Women, % 59% 59% 59%
African-American, % 31% 32% 33%
Current smoking, % 6% 5% 4%
Diabetes mellitus, % 42% 45% 47%
History of MI, % 12% 13% 16%
History of stroke, % 13% 14% 18%
Charlson co-morbidity score ≥ 2, % 50% 54% 63%
Hypertension duration ≥ 10 years 63% 64% 67%
Anti-hypertensive medication
classes
 Mean (SD) 2.6 (1.1) 2.7 (1.2) 2.9 (1.2)
 ≥ 3 51% 55% 63%
SD – standard deviation, BP – blood pressure, MI –myocardial infarction
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Table 2
Mean values of systolic and diastolic blood pressure variability metrics based on the first four measurements 
and first seven measurements.
Systolic blood pressure
First 4 measurements First 7 measurements
Mean ± SD Correlation
with mean





-- -- 135.2 ± 11.7 -- --
SD 12.2 ± 6.4 0.29 <0.001 13.5 ± 5.3 0.36 <0.001
SDIM 12.1 ± 6.0 −0.02 0.500 13.4 ± 4.9 −0.03 0.403
CV 9.0 ± 4.5 0.11 <0.001 9.9 ± 3.7 0.13 <0.001
Peak size 13.9 ± 8.4 0.30 <0.001 20.1 ± 9.7 0.31 <0.001
Trough
size
13.2 ± 7.4 0.24 <0.001 18.0 ± 7.4 0.29 <0.001
SV 16.6 ± 9.2 0.27 <0.001 17.9 ± 7.8 0.33 <0.001
ARV 14.5 ± 8.4 0.26 <0.001 14.9 ± 6.7 0.33 <0.001
Diastolic blood pressure
First 4 measurements First 7 measurements
Mean ± SD Correlation
with mean
p-value Mean ± SD Correlation
with mean
p-value
Mean 75.6 ± 7.6 -- -- 74.8 ± 7.1 -- --
SD 7.0 ± 3.4 0.04 0.154 7.7 ± 2.7 0.03 0.339
SDIM 7.1 ± 3.4 −0.03 0.165 7.8 ± 2.8 −0.06 0.126
CV 9.3 ± 4.6 −0.18 <0.001 10.3 ± 3.8 −0.23 <0.001
Peak size 7.7 ± 4.3 0.03 0.216 10.9 ± 5.0 0.03 0.343
Trough
size
7.7 ± 4.25 0.04 0.145 10.4 ± 4.5 0.07 0.052
SV 9.6 ± 5.0 0.03 0.199 10.3 ± 4.1 0.01 0.702
ARV 8.3 ± 4.6 0.03 0.173 8.6 ± 3.6 0.01 0.788
SD – standard deviation, SDIM – standard deviation independent of the mean, CV – coefficient of variation, SV – successive variation, ARV – 
average real variation.





















MUNTNER et al. Page 14
Table 3
The reproducibility of measures of blood pressure variability based on the first four and second four 
measurements and the first seven and second seven measurements.
Systolic blood pressure
First 4 versus second 4 measurements First 7 versus second 7 measurements
ICC (95% CI) p-value ICC (95% CI) p-value
Mean 0.57 (0.53, 0.60) <0.001 0.64 (0.59, 0.68) <0.001
SD 0.19 (0.13, 0.25) <0.001 0.28 (0.20, 0.34) <0.001
SDIM 0.13 (0.07, 0.18) <0.001 0.22 (0.15, 0.28) <0.001
CV 0.14 (0.09, 0.20) <0.001 0.23 (0.16, 0.29) <0.001
Peak size 0.14 (0.08, 0.19) <0.001 0.18 (0.10, 0.25) <0.001
Trough size 0.17 (0.11, 0.23) <0.001 0.23 (0.16, 0.29) <0.001
SV 0.16 (0.11, 0.22) <0.001 0.26 (0.18, 0.32) <0.001
ARV 0.14 (0.09, 0.20) <0.001 0.25 (0.19, 0.32) <0.001
Diastolic blood pressure
First 4 versus second 4 measurements First 7 versus second 7 measurements
ICC (95% CI) p-value ICC (95% CI) p-value
Mean 0.66 (0.63, 0.69) <0.001 0.70 (0.65, 0.73) <0.001
SD 0.12 (0.07, 0.17) <0.001 0.19 (0.11, 0.26) <0.001
SDIM 0.12 (0.07, 0.17) <0.001 0.18 (0.11, 0.25) <0.001
CV 0.15 (0.10, 0.20) <0.001 0.21 (0.14, 0.27) <0.001
Peak size 0.09 (0.04, 0.14) <0.001 0.14 (0.06, 0.21) <0.001
Trough size 0.11 (0.06, 0.16) <0.001 0.11 (0.04, 0.18) <0.001
SV 0.11 (0.06, 0.16) <0.001 0.12 (0.04, 0.19) <0.001
ARV 0.10 (0.05, 0.15) <0.001 0.11 (0.04, 0.18) <0.001
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Table 4
Cross tabulation of quintiles of standard deviation (top panel) and standard deviation independent of the mean 
(bottom panel) for systolic blood pressure between the first seven versus second seven measurements.
Quintile of SD, second 7 SBP measurements
1 2 3 4 5 Total
Quintile of SD, first 7
SBP measurements
1 43 35 26 33 17 154
2 45 30 27 27 25 154
3 29 32 35 34 27 157
4 24 28 43 25 33 153
5 13 29 24 35 53 154
Total 154 154 155 154 155 772
Quintile of SDIM, second 7 SBP measurements
1 2 3 4 5 Total
Quintile of SDIM, first 7 SBP measurements 1 38 36 33 30 18 155
2 43 23 31 27 29 153
3 32 30 35 28 31 156
4 23 36 31 35 29 154
5 18 29 25 35 47 154
Total 154 154 155 155 154 772
Weighted kappa = 0.14 95% CI = (0.09, 0.19)
Weighted kappa = 0.10 95% CI = (0.05, 0.15)
SBP – systolic blood pressure, SD – standard deviation, SDIM – standard deviation independent of the mean
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Table 5
Association of patient characteristics with low reproducibility of visit-to-visit variability of blood pressure 







Age, years 1.02 (0.99, 1.05) 0.251 1.02 (0.99, 1.06) 0.261
Women 1.50 (1.03, 2.17) 0.034 1.31 (0.89, 1.94) 0.167
African-American 1.38 (0.96, 1.99) 0.087 1.20 (0.81, 1.77) 0.370
Mean SBP, mmHg 1.05 (1.03, 1.06) <0.001 1.04 (1.03, 1.06) <0.001
Mean pulse pressure, mmHg 1.04 (1.02, 1.05) <0.001 0.99 (0.96, 1.02) 0.627
Diabetes mellitus 0.94 (0.66, 1.33) 0.717 0.95 (0.66, 1.38) 0.796
History of myocardial infarction 0.87 (0.53, 1.44) 0.597 0.97 (0.58, 1.64) 0.914
History of stroke 0.84 (0.52, 1.37) 0.488 0.95 (0.57, 1.58) 0.845
History of heart failure 0.73 (0.38, 1.39) 0.341 0.83 (0.43, 1.62) 0.585
Antihypertensive medication class
 ACE Inhibitors 0.93 (0.65, 1.33) 0.691 0.97 (0.67, 1.40) 0.862
 Beta blockers 1.19 (0.83, 1.70) 0.347 1.25 (0.86, 1.82) 0.234
 Calcium channel blockers 1.29 (0.91, 1.84) 0.158 1.08 (0.74, 1.56) 0.711
 Angiotensin receptor blockers 1.73 (1.20, 2.50) 0.004 1.58 (1.07, 2.32) 0.020
 Diuretics 0.93 (0.64, 1.34) 0.698 0.85 (0.58, 1.24) 0.400
Low reproducibility was defined as an absolute difference in the standard deviation of systolic blood pressure ≥ 8 mmHg between the first seven 
and second measurements. This outcome was observed in 20.0% (N=154) patients.
*Adjusted for age, gender, race, and mean systolic blood pressure
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